Evgen Pharma PLC's (LON:EVG) Dr Huw Jones joins Proactive London to go through their portfolio with progress for is lead asset on two fronts in the field of cancer.
Jones firstly addresses the results of the ‘STAR’ Covid-19 trial of its lead asset, ‘SFX-01' which was implemented as an 'opportune' reaction to the global pandemic.
The analyses did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement.
Elsewhere, it has applied to the Food & Drug Administration for orphan drug (OD) status for SFX-01 in the area of glioma, a brain cancer with a very poor prognosis. SFX-01 has also shown some very early promise as a potential leukaemia treatment.
